You can use the interactive chart below to gauge the effect of a change in growth rate on our price estimate.

FORBES: Even Factoring In Big Growth Visa Looks Full At $150

The chart below shows how much Vytorin use has plummeted as Vytorin (in light blue) has gone from being the third-most-prescribed statin drug to one of the least prescribed.

FORBES: FDA Rejects 'Son Of Vytorin'